Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

700
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
700
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

295
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
295
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

571
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
571
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

455
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.2K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabinoids and Symptomatic Bradycardia.

The American journal of the medical sciences·2018
Same author

Secondary Hyperparathyroidism in Heart Failure.

The American journal of the medical sciences·2017
Same author

K<sup>+</sup> and Mg<sup>2+</sup> Dyshomeostasis in Acute Hyperadrenergic Stressor States.

The American journal of the medical sciences·2017
Same author

Regression of Established Cardiac Fibrosis in Hypertensive Heart Disease.

American journal of hypertension·2017
Same author

Targeting the Cardiac Myofibroblast Secretome to Treat Myocardial Fibrosis in Heart Failure.

Circulation. Heart failure·2016
Same author

Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.

JAMA cardiology·2016
Same journal

Providers' Perspectives on Hospital-Based Tobacco Treatment Efforts.

The American journal of the medical sciences·2026
Same journal

In Memoriam: Maurice A. Mufson, MD, MACP.

The American journal of the medical sciences·2026
Same journal

Outcomes of Acute Myeloid Leukemia Patients Admitted to the Intensive Care Unit within 100 days of Allogeneic Hematopoietic Stem Cell Transplantation.

The American journal of the medical sciences·2026
Same journal

Association Between Reverse Triiodothyronine and Cardiac Complications in Patients with Uncontrolled Graves' Disease.

The American journal of the medical sciences·2026
Same journal

Chlorthalidone vs. hydrochlorothiazide in hypertension management: Lessons for guiding clinical practice.

The American journal of the medical sciences·2026
Same journal

The impact of COVID-19 on alcohol-associated hepatitis and alcohol-associated cirrhosis.

The American journal of the medical sciences·2026
See all related articles

Related Experiment Video

Updated: Mar 13, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.8K

Depressed Myocardial Contractility: Can It Be Rescued?

Karl T Weber1

  • 1Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN.

The American Journal of the Medical Sciences
|October 26, 2016
PubMed
Summary
This summary is machine-generated.

Systolic heart failure may not cause irreversible myocardial contractility depression. Thyroid hormone signaling and cardiomyocyte rescue can improve heart function and contractile mass in advanced heart failure patients.

Keywords:
Fetal gene programHeart failureMyocardial contractilityRescue atrophic myocytesThyroid hormone signaling

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.8K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K

Area of Science:

  • Cardiology
  • Molecular Biology
  • Cellular Biology

Background:

  • Current understanding posits irreversible myocardial contractility depression in advanced systolic heart failure.
  • Continuous flow ventricular assist devices (CF-VADs) have shown improved ventricular function, challenging this dogma.
  • This suggests potential for reversing myocardial dysfunction.

Purpose of the Study:

  • To explore cellular and molecular mechanisms underlying the reversal of depressed myocardial contractility.
  • To identify signaling pathways that can restore cardiac function in advanced heart failure.

Main Methods:

  • Investigation of cardiomyocyte thyroid hormone signaling pathways.
  • Analysis of the reexpression of fetal gene programs in cardiomyocytes.
  • Assessment of the rescue of atrophic myocytes and impact on fibrotic microdomains.

Main Results:

  • Thyroid hormone signaling promotes the reexpression of a fetal gene program, enhancing cardiomyocyte efficiency.
  • This signaling pathway aids in rescuing atrophic myocytes, potentially increasing contractile mass.
  • Evidence suggests a mechanism for reversing myocardial depression beyond current therapeutic limitations.

Conclusions:

  • Myocardial contractility depression in advanced systolic heart failure may be reversible.
  • Thyroid hormone signaling is a key mechanism for restoring cardiomyocyte function and efficiency.
  • Targeting these pathways offers novel therapeutic strategies for heart failure treatment.